Travere Therapeutics (TVTX) Long-Term Debt Repayments (2013 - 2025)
Travere Therapeutics' (TVTX) quarterly Long-Term Debt Repayments came in at $211.3 million in Q1 2022, up 1600839.39% on a QoQ basis from $13200.0 in Q1 2013.
Powered by 
Analysis
Travere Therapeutics (TVTX) Long-Term Debt Repayments (2013 - 2025) Analysis & Trends
Travere Therapeutics (TVTX) has 2 years of Long-Term Debt Repayments data on file, last reported at $211.3 million in Q1 2022.
- Quarterly Long-Term Debt Repayments changed N/A year-over-year to $211.3 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $211.3 million (changed N/A YoY) and the FY2025 annual result came in at $68.9 million, changed N/A from the prior year.
- Long-Term Debt Repayments advanced to $211.3 million in Q1 2022, from $13200.0 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $211.3 million in Q1 2022 to a low of $211.3 million in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 17.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Travere Therapeutics | 6.11 Bn | 6.11 Bn | 162.52 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 68.90 Mn |
| Mar 31, 2022 | 211.32 Mn |
| Mar 31, 2013 | 13,200.00 |